Core Viewpoint - *ST Shuangcheng has no current plans to acquire a semiconductor company and is actively taking measures to mitigate the risk of delisting by enhancing its marketing strategies and international sales efforts [1] Group 1: Marketing and Sales Strategies - The company is adapting to new national medical insurance and procurement policies to increase sales volume of existing products [1] - Efforts are being made to enhance international sales, particularly following the approval of its injectable paclitaxel (albumin-bound) for legal sale in the U.S., which boosts market competitiveness [1] Group 2: Export and Production - The company aims to maintain existing customer orders in its peptide business while expanding its customer base and utilizing the increased purification capacity of its expanded peptide workshop [1] - Active promotion of pending product approvals and ANDA submissions in the U.S., Canada, and other countries is underway, alongside efforts to secure more CDMO projects and technical collaborations [1] Group 3: CMO Cooperation and Cost Control - The company is leveraging its GMP capabilities in sterile products to pursue external CMO collaborations, particularly with major clients [1] - Continuous cost control measures are being implemented, focusing on optimizing personnel configuration, enhancing efficiency, ensuring reasonable procurement, and monitoring expense rationality [1]

Core Viewpoint - The company Jiangsu Zhongli Group Co., Ltd. has received a special verification opinion regarding its compliance with the Shenzhen Stock Exchange's regulations, indicating that it meets the conditions for the removal of delisting risk warnings due to improvements in its financial situation and internal controls [2][6][18]. Financial Performance - For the fiscal year 2024, the company reported a net asset value of 1.42 billion RMB, with an operating revenue of 2.358 billion RMB [8][18]. - The company’s 2024 financial statements received a standard unqualified audit opinion, indicating that previous issues related to going concern uncertainties and related party transactions have been resolved [6][8]. Compliance with Regulations - The company has confirmed that it meets the criteria for the removal of delisting risk warnings as per the revised stock listing rules, specifically Article 9.3.8, and does not fall under any conditions for mandatory delisting as outlined in Article 9.3.12 [9][18]. - The company has addressed previous concerns regarding internal control deficiencies and has received a standard unqualified opinion on its internal control audit for 2024 [15][18]. Risk Management - The company has successfully eliminated the significant uncertainties related to its ongoing operations and has resolved issues concerning the misuse of funds and guarantees [6][8][18]. - The company has taken necessary steps to ensure compliance with the Shenzhen Stock Exchange's requirements, including the submission of relevant documentation and reports to support its claims [12][18].

Group 1 - The company *ST Weidi (603023)* has announced the cancellation of its delisting risk warning, with the stock being suspended for one day and set to resume trading on June 4, 2025 [1] - Following the cancellation, the stock's name will change to "Weidi Co., Ltd." and the daily price fluctuation limit will be adjusted to 10% [1] - For the fiscal year 2024, the company reported a net profit of 5.0555 million yuan, with a net profit of 4.1528 million yuan after deducting non-recurring gains and losses, both achieving positive values, which meets the conditions for the cancellation of the delisting risk warning [1]

Group 1: Company Operations and Financial Status - The company is currently in the construction preparation phase for its astaxanthin project [1] - The board aims to improve the company's operational and financial conditions to enhance overall competitiveness and achieve the goal of lifting the delisting risk warning by 2025 [2] - If the company encounters specific situations outlined in the Stock Listing Rules in 2025, its shares will be terminated from listing [2] Group 2: Core Business Focus - The company's main business operations include agriculture (including astaxanthin) and military industry, which will remain the core areas for future development [3] Group 3: Mergers and Acquisitions - Future merger and acquisition activities will be announced through company announcements [4] - The company is encouraged to expedite mergers or restructuring to strengthen its operations, especially in light of the relaxed policies on mergers and acquisitions [7] Group 4: Legal and Shareholder Issues - The court ruling regarding the financial loan dispute indicates a risk of change in the controlling shareholder, which may affect the company's management and operations [5][7] - The major shareholder's 90,860,000 shares, accounting for 29.18% of the total share capital, are subject to sale to repay debts [5] Group 5: Product Development and Market Strategy - The company is accelerating the construction of the astaxanthin project and increasing investment to build an ecological chain for the astaxanthin industry [7] - The company has launched astaxanthin eggs and is developing skincare products, with collaborations established for further research and development [7]

Group 1 - The company *ST Kexin (600234) has met the conditions set forth in Article 9.3.7 of the Stock Listing Rules and has applied to revoke the delisting risk warning, which has been approved by the Shanghai Stock Exchange [1] - The company's stock will be suspended for one day on May 19, 2025, and will resume trading on May 20, 2025, with the stock name changing from "*ST Kexin" to "Kexin Development" [1] - For the fiscal year 2024, the company achieved an operating income of 375 million yuan and a net profit attributable to the parent company of 39.977 million yuan, with a net profit of 8.1013 million yuan after deducting non-recurring gains and losses [1] Group 2 - The daily price fluctuation limit for the company's stock will change from 5% to 10% [1]